Travere Therapeutics
TVTX
175 hedge funds and large institutions have $677M invested in Travere Therapeutics in 2024 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 64 increasing their positions, 48 reducing their positions, and 21 closing their positions.
48% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 21
33% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 48
6% more funds holding
Funds holding: 165 → 175 (+10)
4.07% less ownership
Funds ownership: 119.41% → 115.35% (-4.1%)
16% less capital invested
Capital invested by funds: $807M → $677M (-$129M)
81% less call options, than puts
Call options by funds: $1.09M | Put options by funds: $5.82M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$10.6M |
| 2 |
EP
Eversept Partners
New York
|
+$8.06M |
| 3 |
Millennium Management
New York
|
+$7.65M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.36M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$40M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$9.84M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$7.43M |
| 4 |
Goldman Sachs
New York
|
-$6.51M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$5.72M |
TVTX Hedge Fund Activity: Q1 2024 in Review
175 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q1 2024, worth a combined $677M — down 16% from $807M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new TVTX positions and 21 closed out — a net gain of 10 holders — while 64 added to existing stakes and 48 trimmed.
The largest buyer was State Street, adding an estimated $10.6M. The largest seller was Morgan Stanley, cutting an estimated $40M.
- 175 institutional investors held Travere Therapeutics (TVTX) as of Q1 2024, up from 165 in Q4 2023.
- Funds reported $677M of Travere Therapeutics stock for Q1 2024, down 16% quarter-over-quarter.
- 31 funds opened new Travere Therapeutics positions in Q1 2024 and 21 closed out, a net change of +10 holders.
- The largest Travere Therapeutics buyer in Q1 2024 was State Street, an estimated $10.6M added.
- The largest Travere Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $40M sold.
Based on aggregated 13F filings for Q1 2024.